No insider purchase over the last 90 days. The latest was filed 05 Mar 2025.
Talkspace, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Talkspace, Inc. logged 59 filings by 13 insiders.
The flow runs one way only: 1 sale worth €41k, from 1 insider, and no purchase. One trade stands out by size: a sale of €41k from Margolin Gil, disclosed on 15 December 2025.
The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (5,458 companies, median 22 filings), a count of 59 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed 8 purchases and 5 sales. The 10-K for the year ended 31 December 2025 shows 228.9 m USD of revenue and 7.8 m USD of net income.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Analysts rate Talkspace, Inc. Buy (bullish), based on 4 analysts. Average price target: US$6.38.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 200 declarations
Talkspace, Inc. is a U.S.-based digital health company focused on virtual behavioral healthcare. The company is listed on the NASDAQ market in the United States under the ticker TALK. Founded in 2012 and headquartered in New York, Talkspace built its early brand around a differentiated concept: enabling people to message with a licensed therapist anytime, from anywhere. That message-based therapy model later expanded into a broader virtual mental health offering, positioning the company as one of the best-known brands in online behavioral care. ([investors.talkspace.com](https://investors.talkspace.com/))
From an operating perspective, Talkspace runs a multi-line platform that spans individual therapy, couples therapy, teen therapy, psychiatry, and medication management for adults. Care can be delivered through live video, audio, live chat, or asynchronous messaging, all within an encrypted web and mobile platform designed to meet HIPAA and federal and state regulatory requirements. The company also offers self-guided tools and resources, giving it a broader product set than a pure therapy marketplace. Management states that its network includes 5,000+ licensed clinicians with expertise across more than 150 conditions and treatment modalities. ([investors.talkspace.com](https://investors.talkspace.com/))
Talkspace’s competitive position is anchored in network scale, payer relationships, and enterprise distribution. The company says it reaches more than 130 million covered lives through health plans, employee benefits programs, and business partnerships. It also describes itself as the largest in-network provider of virtual mental health therapy in the United States, a claim that matters in a market where competitors include telehealth specialists, broader digital health platforms, and payer-led behavioral health initiatives. For investors, the key question is not only user acquisition, but also reimbursement quality, clinician supply, retention, and the company’s ability to shift mix toward higher-quality institutional channels. ([investors.talkspace.com](https://investors.talkspace.com/))
Recent developments have been materially important. In its February 2026 full-year 2025 results, Talkspace reported 2025 revenue of $228.9 million, up 22% year over year, and guided for 2026 revenue of $275 million to $290 million with adjusted EBITDA of $30 million to $35 million. Management highlighted continued expansion in payer revenue and improving operating leverage, while consumer revenue remained weaker. In March 2026, Talkspace also announced that Universal Health Services would acquire the company, making this a major strategic and valuation event for shareholders. ([investors.talkspace.com](https://investors.talkspace.com/node/10196/pdf))
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2025 | 228.9 m USD | 7.8 m USD | 0.04 USD | 10-K |
| Dec 2024 | 27.6 m USD | 1.1 m USD | 0.01 USD | 10-K |
| Dec 2023 | 25.3 m USD | -19.2 m USD | -0.12 USD | 10-K |
| Dec 2022 | 119.6 m USD | -79.7 m USD | -0.51 USD | 10-K |
| Dec 2021 | 113.7 m USD | -62.7 m USD | -0.72 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.